Published in Am J Gastroenterol on October 01, 2003
Primary biliary cirrhosis. Semin Immunopathol (2009) 1.46
Primary biliary cirrhosis. Orphanet J Rare Dis (2008) 1.31
Hepatic osteodystrophy: An important matter for consideration in chronic liver disease. World J Hepatol (2011) 0.94
Cholestasis and metabolic bone disease - a clinical review. Wien Med Wochenschr (2008) 0.89
Primary sclerosing cholangitis--what is the difference between east and west? World J Gastroenterol (2008) 0.88
Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis (2012) 0.88
Clinical features and management of primary biliary cirrhosis. World J Gastroenterol (2008) 0.85
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol (2015) 0.83
Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci (2006) 0.78
Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation. Transplant Res (2012) 0.78
Strengthening the bones in primary biliary cirrhosis. Hepatology (2013) 0.77
Osteoporosis across chronic liver disease. Osteoporos Int (2016) 0.76
Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Curr Treat Options Gastroenterol (2003) 0.76
Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y) (2006) 0.75
Diagnosis and Management of Cirrhosis-Related Osteoporosis. Biomed Res Int (2016) 0.75
Concept on the pathogenesis and treatment of primary biliary cirrhosis. World J Gastroenterol (2006) 0.75
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
Role of a research ethics committee in follow-up and publication of results. Lancet (2003) 3.61
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (2002) 2.86
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology (2002) 2.34
TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology (2002) 2.12
Prospective comparison of whole-body (18)F-FDG PET/CT and MRI of the spine in the diagnosis of haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging (2014) 2.06
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
[2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis]. Reumatol Clin (2011) 2.02
[Intake of calcium, magnesium and sodium through water: health implications]. Med Clin (Barc) (2008) 2.02
[A secure job for ever]. Med Clin (Barc) (2003) 2.01
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology (2006) 1.96
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol (2003) 1.90
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Hepatorenal syndrome. Lancet (2003) 1.86
Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol (2008) 1.83
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: response to therapy of entheseal abnormalities. J Rheumatol (2010) 1.82
Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum (2008) 1.80
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (2003) 1.64
Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology (2014) 1.60
MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology (2005) 1.58
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology (2009) 1.50
Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J (2006) 1.50
Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. Blood (2013) 1.49
Validation and application of the sentinel lymph node concept in malignant vulvar tumours. Eur J Nucl Med Mol Imaging (2006) 1.46
[Organization and functioning model of biomedical research structures. Situation and future challenges]. Med Clin (Barc) (2008) 1.46
[Relationship between C-telopeptides of type I collagen serum values with bone mineral density and antiosteoporotic drug intake in postmenopausal women. Preliminary data from the FRODOS study]. Med Clin (Barc) (2009) 1.41
[Deaths by a medical resident. Could they have been avoided?]. Med Clin (Barc) (2003) 1.38
Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology (2002) 1.35
Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology (2005) 1.35
Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology (2010) 1.29
2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging (2009) 1.24
Effect of vertebroplasty on pain relief, quality of life, and the incidence of new vertebral fractures: a 12-month randomized follow-up, controlled trial. J Bone Miner Res (2012) 1.23
18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging (2009) 1.20
Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum (2008) 1.18
Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology (2004) 1.18
Bacterial infections in cirrhosis. Liver Int (2004) 1.06
Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology (2003) 1.05
Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics. Alcohol Clin Exp Res (2005) 1.04
Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol (2003) 1.02
Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology (2005) 1.01
Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol (2005) 1.01
25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone (2012) 1.01
Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology (2003) 1.00
Application of 16S rRNA gene-targetted fluorescence in situ hybridization and restriction fragment length polymorphism to study porcine microbiota along the gastrointestinal tract in response to different sources of dietary fibre. FEMS Microbiol Ecol (2006) 0.99
Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause (2010) 0.97
Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol (2004) 0.97
Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol (2002) 0.96
Is the identification of in-transit sentinel lymph nodes in malignant melanoma patients really necessary? Eur J Nucl Med Mol Imaging (2004) 0.96
Camptocormia as a clinical manifestation of mitochondrial myopathy. Clin Rheumatol (2006) 0.95
Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology (2010) 0.95
Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med Mol Imaging (2002) 0.95
The European board of nuclear medicine fellowship examination. Eur J Nucl Med Mol Imaging (2006) 0.95
Osteomalacia revisited : a report on 28 cases. Clin Rheumatol (2010) 0.94
Incidence of skeletal fractures after traumatic spinal cord injury: a 10-year follow-up study. Clin Rehabil (2013) 0.94
Natural history of primary biliary cirrhosis. Clin Liver Dis (2003) 0.94
The effects of short-term iron supplementation on iron status in infants in malaria-endemic areas. Am J Trop Med Hyg (2004) 0.94
Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin Arthritis Rheum (2002) 0.94
Clinical relevance of sentinel lymph nodes in the internal mammary chain in breast cancer patients. Eur J Nucl Med Mol Imaging (2005) 0.93
Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging (2013) 0.93
Increased apoptosis dependent on caspase-3 activity in polymorphonuclear leukocytes from patients with cirrhosis and ascites. J Hepatol (2004) 0.90
Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem (2007) 0.90
Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol (2004) 0.89
Are angiotensin II receptor antagonists useful strategies in steatotic and nonsteatotic livers in conditions of partial hepatectomy under ischemia-reperfusion? J Pharmacol Exp Ther (2008) 0.89
Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology (2003) 0.89
Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol (2006) 0.89
Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med (2004) 0.88